Literature DB >> 32988815

Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".

Minh Patrick Lê1,2, Christine Le Beller3, Quentin Le Hingrat4,5, Pierre Jaquet6, Paul-Henri Wicky7, Vincent Bunel7, Laurent Massias8,5, Benoit Visseaux4,5, Jonathan Messika7, Diane Descamps4,5, Hervé Mal7, Jean-François Timsit5,6, Gilles Peytavin8,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32988815      PMCID： PMC7674048          DOI： 10.1128/AAC.01937-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Care for Critically Ill Patients With COVID-19.

Authors:  Srinivas Murthy; Charles D Gomersall; Robert A Fowler
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

2.  Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.

Authors:  Victoria C Yan; Florian L Muller
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

3.  Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.

Authors:  Massimo Tempestilli; Priscilla Caputi; Valeria Avataneo; Stefania Notari; Olindo Forini; Laura Scorzolini; Luisa Marchioni; Tommaso Ascoli Bartoli; Concetta Castilletti; Eleonora Lalle; Maria R Capobianchi; Emanuele Nicastri; Antonio D'Avolio; Giuseppe Ippolito; Chiara Agrati
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

4.  Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.

Authors:  Andrea J Pruijssers; Amelia S George; Alexandra Schäfer; Sarah R Leist; Lisa E Gralinksi; Kenneth H Dinnon; Boyd L Yount; Maria L Agostini; Laura J Stevens; James D Chappell; Xiaotao Lu; Tia M Hughes; Kendra Gully; David R Martinez; Ariane J Brown; Rachel L Graham; Jason K Perry; Venice Du Pont; Jared Pitts; Bin Ma; Darius Babusis; Eisuke Murakami; Joy Y Feng; John P Bilello; Danielle P Porter; Tomas Cihlar; Ralph S Baric; Mark R Denison; Timothy P Sheahan
Journal:  Cell Rep       Date:  2020-07-07       Impact factor: 9.423

5.  Acute Kidney Injury in SARS-CoV-2 Infection: Direct Effect of Virus on Kidney Proximal Tubule Cells.

Authors:  Manoocher Soleimani
Journal:  Int J Mol Sci       Date:  2020-05-05       Impact factor: 5.923

6.  Acute kidney injury in patients with COVID-19: an update on the pathophysiology.

Authors:  Hassan Izzedine; Kenar D Jhaveri
Journal:  Nephrol Dial Transplant       Date:  2021-01-25       Impact factor: 5.992

7.  Acute kidney injury in SARS-CoV-2 infected patients.

Authors:  Vito Fanelli; Marco Fiorentino; Vincenzo Cantaluppi; Loreto Gesualdo; Giovanni Stallone; Claudio Ronco; Giuseppe Castellano
Journal:  Crit Care       Date:  2020-04-16       Impact factor: 9.097
  8 in total
  2 in total

1.  Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.

Authors:  Carlos K H Wong; Ivan C H Au; Wing Yiu Cheng; Kenneth K C Man; Kristy T K Lau; Lung Yi Mak; Sing Leung Lui; Matthew S H Chung; Xi Xiong; Eric H Y Lau; Benjamin J Cowling
Journal:  Aliment Pharmacol Ther       Date:  2022-03-22       Impact factor: 9.524

2.  A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.

Authors:  Tyler W Ackley; Dayna McManus; Jeffrey E Topal; Brian Cicali; Sunish Shah
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.